[go: up one dir, main page]

WO2022039701A1 - Composition orale solide comprenant de l'eltrombopag choline - Google Patents

Composition orale solide comprenant de l'eltrombopag choline Download PDF

Info

Publication number
WO2022039701A1
WO2022039701A1 PCT/TR2021/050799 TR2021050799W WO2022039701A1 WO 2022039701 A1 WO2022039701 A1 WO 2022039701A1 TR 2021050799 W TR2021050799 W TR 2021050799W WO 2022039701 A1 WO2022039701 A1 WO 2022039701A1
Authority
WO
WIPO (PCT)
Prior art keywords
solid oral
oral composition
less
composition according
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2021/050799
Other languages
English (en)
Inventor
Fatih Sunel
Gulcin TOK
Bulent DEMIR
Selin KOKSAL UZUN
Salih Sermet BASARAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Priority to EP21858732.7A priority Critical patent/EP4199921A4/fr
Publication of WO2022039701A1 publication Critical patent/WO2022039701A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Definitions

  • the present invention relates to a solid oral composition comprising eltrombopag choline and at least one pharmaceutically acceptable excipient.
  • the present invention also relates to a simple, rapid, cost effective, time-saving and industrially convenient process.
  • THPO Thrombopoietin
  • MGDF megakaryocyte growth and development factor
  • thrombopoietin receptor agonists mimic the action of thrombopoietin on its receptor and stimulate the activation, proliferation and maturation of megakaryocytes, resulting in an increase in circulating platelet counts.
  • Thrombopoietin itself acts in this manner, but when recombinant thrombopoietins were used clinically, they were found to cause rebound thrombocytopenia, probably due to induction of anti-thrombopoietin antibodies. For this reason, direct administration of thrombopoietin was abandoned as an approach to treating thrombocytopenia and other approaches for activating the thrombopoietin receptor were sought.
  • thrombopoietin receptor agonists Two thrombopoietin receptor agonists were subsequently developed and are now in clinical use for chronic idiopathic thrombocytopenic purpura (ITP) and for other thrombocytopenic conditions.
  • Eltrombopag is an orally active thrombopoietin receptor agonist with megakaryopoiesis stimulating activity. Eltrombopag binds to and stimulates the platelet thrombopoietin receptor (TPO-R or CD110), a member of the hematopoietin receptor superfamily. Activation of TPO- R leads to the proliferation and differentiation of megakaryocytes, thereby increasing the production of blood platelets.
  • TPO-R platelet thrombopoietin receptor
  • eltrombopag 3-[3-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1 H- pyrazol-4-yl]diazenyl]-2-hydroxyphenyl] benzoic acid and its chemical structure is shown in the Formula 1 .
  • Eltrombopag is marketed under the trade name Promacta® by GlaxoSmithKline and Ligand Pharmaceuticals as eltrombopag olamine for the treatment of conditions leading to thrombocytopenia.
  • Eltrombopag has been disclosed in U.S. Patent Nos. 7,332,481 and 7,160,870, as well as WO 01/89457; and in EP Patent No. 1 ,294,378.
  • Eltrombopag bisethanolamine salt and eltrombopag olamine salt has been disclosed in WO 03/098992 and U.S. Patent No. 8,052,994, respectively.
  • Some of the concerns is that slow dissolution of the compound from solid dosage forms, the tendency of the compound to form insoluble metal complexes when contacted with excipients that contain a coordinating metal, and the tendency of the compound to under-go a Maillard reaction when contacted with excipients that contain reducing sugars.
  • compositions comprising the new eltrombog salt are needed.
  • WO 19/071111A1 discloses eltrombopag choline.
  • the solid state form of eltrombopag choline disclosure have advantageous properties chemical or polymorphic purity, dissolution profile, bioavailability, morphology or crystal habit, stability - such as chemical stability as well as thermal and mechanical stability with respect to polymorphic conversion, stability towards dehydration and/or storage stability, a lower degree of hygroscopicity, low content of residual solvents.
  • a solid oral composition comprising eltrombopag choline is improved for the treatment of conditions leading to thrombocytopenia. It is used to overcome the disadvantages and side effects of the active agent’s other salts meanwhile increasing the dissolution rate and stability in the desired manner.
  • the main object of the present invention is to eliminate problems and bringing additional advantages to the relevant prior art.
  • the more clearly main object of the present invention is to provides a solid oral composition comprising eltrombopag choline having desired dissolution profile, stability (chemical stability or towards dehydration and/or storage stability) for the treatment of conditions leading to thrombocytopenia.
  • Another object of the present invention is to provides a process for a solid oral composition comprising eltrombopag choline.
  • the process is a simple, rapid, cost effective, time-saving and industrially convenient method.
  • a solid oral composition comprising eltrombopag choline and at least one pharmaceutically acceptable excipient.
  • the solid state form of eltrombopag choline has advantageous properties chemical or polymorphic purity, dissolution profile, bioavailability, stability. While creating the formulation for the treatment of conditions leading to thrombocytopenia, using eltrombopag choline was achieved effective treatment by making a low cost and easy production.
  • the amount of eltrombopag choline is between 3.0% and 40.0% by weight in the total formulation. This amount provides an effective treatment for the treatment of conditions leading to thrombocytopenia.
  • the amount of eltrombopag choline is between 5.0% and 35.0%, between 6.0% and 30.0%, between 7.0% and 27.0%, by weight in the total formulation.
  • excipients provided in a formulation may positively or negatively influence the physicochemical and pharmacokinetic properties, e.g. the solubility, absorption, bioavailability of an active agent. For this reason, the excipients which accompany an active agent have to be selected in a careful and conscious manner while a formulation is developed.
  • the formulations should have no physicochemical incompatibility between the active agents and the excipients. In the present invention, all excipients selected are compatible with eltrombopag choline.
  • Suitable diluents are selected from the group comprising microcrystalline cellulose, starch, pregelatinize starch, powdered cellulose, mannitol, spray-dried mannitol, dextrose, sucrose, sorbitol, xylitol, inorganic salts, polysaccharides, dicalcium phosphate, sodium chloride, dextrates, lactitol, maltodextrin, sucrose-maltodextrin mixture, trehalose, sodium carbonate, sodium bicarbonate or mixtures thereof.
  • the amount of diluents is between 45.0% and 90.0% by weight in the total formulation.
  • the amount of diluents is between 50.0% and 85.0% by weight in the total formulation.
  • the diluent is microcrystalline cellulose or mannitol or mixtures thereof.
  • Suitable binders are selected from the group comprising polyvinylpyrrolidone, sodium carboxymethyl cellulose, polyethylene glycol, polyvinyl alcohol, pregelatinized starch, natural gums, sucrose, sodium alginate, gelatin, carrageenan, guar gum, carbomer, polymethacrylates, methacrylate polymers, gelatin, alginate, alginic acid, xanthan gum, hyaluronic acid, pectin, polysaccharides, carbomer, poloxamer, polyacrylamide, polyoxyethylene-alkyl ether, polydextrose, polyethylene oxide or mixtures thereof.
  • the amount of binders is between 0.05% and 10.0% by weight in the total formulation. Preferably, it is between 0.1% and 5.0% by weight in the total formulation.
  • used binder’s rate is very important in the solid oral composition. Thanks to the rate, dissolution problems are solved and surprisingly better dissolution profile is gained.
  • the binder is polyvinylpyrrolidone.
  • the active ingredient did not interact at polyvinylpyrrolidone, and polyvinylpyrrolidone also ensured that the composition had the desired dissolution profile.
  • Suitable disintegrants are selected from the group comprising croscarmellose sodium, sodium starch glycolate, starch, crospovidone, low-substituted hydroxypropyl cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, docusate sodium, guar gum, low substituted hydroxypropyl cellulose, polyacryline potassium, sodium alginate, corn starch, alginic acid, alginates, ion-exchange resins, sodium dodesyl sulphate, poloxamer, sodium glycine carbonate or mixtures thereof.
  • the amount of disintegrants is between 1.0% and 25.0% by weight in the total formulation. Preferably, it is between 1.0% and 20.0%, between 1 .0% and 15.0% by weight in the total formulation.
  • the disintegrant is croscarmellose sodium or sodium starch glycolate or mixtures thereof.
  • Suitable lubricants are selected from the group comprising sodium stearyl fumarate, magnesium stearate, calcium stearate, zinc stearate, boric acid, hydrogenated vegetable oil, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate, polyethylene glycol or mixtures thereof.
  • the amount of the lubricants is 0.1% to 5.0% or 0.1% to 4.0% by weight of the total composition.
  • the lubricant is sodium stearyl fumarate.
  • Suitable glidants are selected from the group comprising colloidal silicon dioxide, corn starch, talc or mixtures thereof.
  • the amount of the glidants is 0.05% to 5.0% or 0.05% to 3.0% by weight of the total composition.
  • the glidant is colloidal silicon dioxide.
  • particle size distribution means the cumulative volume size distrubition as tested by any conventionally accepted method such as the laser diffraction method (i.e. malvern analysis) .
  • d(0.9) means, the size at which 90% by volume of the particles are finer.
  • eltrombopag choline has a particle size of d(0.9) less than 150 pm or less than 140 pm or less than 130 pm or less than 120 pm or less than 110 pm or less than 100 pm or less than 90 pm or less than 80 pm or less than 70 pm or less than 60 pm or less than 50 pm or less than 40 pm or less than 30 pm or less than 20 pm. This property provides improved flow properties, also it helps to provide the desired dissolution profile. According to one embodiment of the invention, eltrombopag choline has a particle size of d(0.9) less than 10 pm.
  • the solid oral composition is in the form of tablets, capsules, strips, powders, pastilles, sachets, effervescent compositions, pills, coated bead systems, granules, microspheres, dragees, films.
  • the solid oral composition is in the form of tablets or capsules.
  • the solid oral composition is in the form of tablet and the tablet are coated film-coating comprising coating agents.
  • Suitable coating agents are selected from the group comprising copovidone, polymethacrylates, polydextrose, polyethoxylated sorbitan, oleic acid, polyalkylacrylates copolymers, triacetin, hydroxyl propyl methyl cellulose, colloidal silicon dioxide, lactose monohydrate, medium chain triglycerides, hydroxypropyl cellulose, white wax, polyvinyl alcohol, polyethylene glycol, talc, polyvinyl alcohol-polyethylene glycol copolymers (Kollicoat® IR), ethylcellulose dispersions (Surelease®), polyvinylprolidone, polyvinylprolidone-vinyl acetate copolymer (PVP-VA), all kinds of Opadry®, pigments, dyes, titanium dioxide, iron oxide or mixtures thereof.
  • the solid oral composition can be prepared as tablet form.
  • Tablet comprises at least one type of particle, for example; mini-tablets, pellets, core, agglomerates, granules, powders, liposomes, sphericals or mixtures thereof.
  • the solid oral composition is formulated as capsule form.
  • Capsule comprises at least one type of particle, for example; mini-capsules, mini-tablets, pellets, core, agglomerates, granules, powders, liposomes, sphericals or mixtures thereof.
  • the solid form composition of the present invention may be prepared, using standard techniques and manufacturing processes well known in the art, such as direct compression, wet or dry granulation, hot melt granulation, hot melt extrusion, fluidized bed granulation, extrusion/spheronization, slugging, spray drying and solvent evaporation.
  • the solid oral composition is obtained by using a wet granulation method therefore, a simple and low-cost production method was employed.
  • the solid oral composition comprises;
  • the solid oral composition comprises;
  • Example 1 The solid oral composition comprising eltrombopag choline
  • Example 2 The tablet formulation comprising eltrombopag
  • Example 3 The tablet formulation comprising eltrombopag
  • Process for example 2 or 3 a) Mixing eltrombopag choline, microcrystalline cellulose, mannitol, polyvinylpyrrolidone, b) Granulating the mixture with water in a high-shear wet granulator, c) Wet milling the granule and drying in fluid bed dryer, d) Sieving the mixture and obtained homogeneous powder, e) Adding microcrystalline cellulose, disintegrant (croscarmellose sodium or sodium starch glycolate), colloidal silicon dioxide and mixing, f) Adding sodium stearyl fumarate and mixing, g) Compressing the mixture to form of a tablet, h) Coating tablets.
  • a) Mixing eltrombopag choline, microcrystalline cellulose, mannitol, polyvinylpyrrolidone b) Granulating the mixture with water in a high-shear wet granulator, c) Wet milling the granule and drying in

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition orale solide comprenant de l'eltrombopag choline et au moins un excipient pharmaceutiquement acceptable. La présente invention concerne également un procédé simple, rapide, économique, économe en temps et pratique industriellement.
PCT/TR2021/050799 2020-08-21 2021-08-13 Composition orale solide comprenant de l'eltrombopag choline Ceased WO2022039701A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP21858732.7A EP4199921A4 (fr) 2020-08-21 2021-08-13 Composition orale solide comprenant de l'eltrombopag choline

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2020/13232A TR202013232A2 (tr) 2020-08-21 2020-08-21 Eltrombopag kolin içeren katı oral kompozisyon
TR2020/13232 2020-08-21

Publications (1)

Publication Number Publication Date
WO2022039701A1 true WO2022039701A1 (fr) 2022-02-24

Family

ID=80323655

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2021/050799 Ceased WO2022039701A1 (fr) 2020-08-21 2021-08-13 Composition orale solide comprenant de l'eltrombopag choline

Country Status (3)

Country Link
EP (1) EP4199921A4 (fr)
TR (1) TR202013232A2 (fr)
WO (1) WO2022039701A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117281780A (zh) * 2023-11-24 2023-12-26 山东则正医药技术有限公司 一种艾曲泊帕乙醇胺干混悬剂及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017042839A1 (fr) * 2015-09-08 2017-03-16 Actavis Group Ptc Ehf. Nouveau sel d'eltrombopag et préparation de celui-ci
EP3409272A1 (fr) * 2018-03-07 2018-12-05 Alfred E. Tiefenbacher (GmbH & Co. KG) Composition pharmaceutique comprenant de l'eltrombopag olamine, du sucre réducteur et un liant polymérique
WO2019071111A1 (fr) * 2017-10-06 2019-04-11 Teva Pharmaceuticals Usa, Inc. Formes à l'état solide d'eltrombopag choline

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018078644A1 (fr) * 2016-10-24 2018-05-03 Hetero Labs Limited Comprimés d'eltrombopag à désintégration orale
EP3829576A4 (fr) * 2018-08-02 2022-05-11 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Composition pharmaceutique comprenant de l'eltrombopag olamine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017042839A1 (fr) * 2015-09-08 2017-03-16 Actavis Group Ptc Ehf. Nouveau sel d'eltrombopag et préparation de celui-ci
WO2019071111A1 (fr) * 2017-10-06 2019-04-11 Teva Pharmaceuticals Usa, Inc. Formes à l'état solide d'eltrombopag choline
EP3409272A1 (fr) * 2018-03-07 2018-12-05 Alfred E. Tiefenbacher (GmbH & Co. KG) Composition pharmaceutique comprenant de l'eltrombopag olamine, du sucre réducteur et un liant polymérique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP4199921A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117281780A (zh) * 2023-11-24 2023-12-26 山东则正医药技术有限公司 一种艾曲泊帕乙醇胺干混悬剂及其制备方法
CN117281780B (zh) * 2023-11-24 2024-02-02 山东则正医药技术有限公司 一种艾曲泊帕乙醇胺干混悬剂及其制备方法

Also Published As

Publication number Publication date
TR202013232A2 (tr) 2022-03-21
EP4199921A1 (fr) 2023-06-28
EP4199921A4 (fr) 2024-09-25

Similar Documents

Publication Publication Date Title
JP4575594B2 (ja) 経口用固体剤形のエプロサルタン配合の生体内強化性処方
ZA200309289B (en) Oxcarbazepine dosage forms.
JP6768984B2 (ja) 酢酸亜鉛水和物錠及びその製造方法
AU2019321583C1 (en) Formulations of AG10
US20210308104A1 (en) Pharmaceutical composition comprising eltrombopag olamine
WO2022060332A1 (fr) Formulation pharmaceutique orale solide comprenant de l'eltrombopag olamine
US20090155369A1 (en) Pharmaceutical composition containing levodopa, entacapone and carbidopa
EP4199921A1 (fr) Composition orale solide comprenant de l'eltrombopag choline
CN104254321A (zh) 稳定性提高的药物制剂
WO2016079687A1 (fr) Composition pharmaceutique orale de tériflunomide
KR20210038414A (ko) 안정화제를 함유하는 의약품의 고형 제제
EP2480234A2 (fr) Composition de ranolazine à libération prolongée
US11260055B2 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
EP4054566A1 (fr) Capsule comprenant de l'eltrombopag olamine
JP2021528381A (ja) ドーパミン−β−ヒドロキシラーゼ阻害剤を含む製剤及び該製剤の調製方法
WO2025170558A1 (fr) Formulation pharmaceutique orale solide comprenant de l'avatrombopag
KR102488167B1 (ko) 피롤카르복사미드의 고형 조성물
EP4599824A1 (fr) Formulation pharmaceutique orale solide comprenant de l'avatrombopag
EP3366281A1 (fr) Compositions pharmaceutiques orales solides d'ivabradine
CA3187241A1 (fr) Compositions pharmaceutiques comprenant du ribociclib
US20110028526A1 (en) Valsartan solid oral dosage forms and methods of making such formulations
JP2014031359A (ja) バラシクロビル塩酸塩２型結晶を含有する錠剤とその製法
WO2005092319A1 (fr) Compositions pharmaceutiques a desintegration rapide, comprenant du nateglinide et un delitant
JP2022086833A (ja) 酢酸亜鉛含有医薬組成物
RU2007147951A (ru) Фармацевтические рецептуры немикронизированного (4-хлорфенил){4-(4-пиридилметил)-фталазин-1-ила} и его солей с немедленным высвобождением и высоким содержанием лекарственного средства

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21858732

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021858732

Country of ref document: EP

Effective date: 20230321

WWW Wipo information: withdrawn in national office

Ref document number: 2021858732

Country of ref document: EP